Polyamine reduced diet and low dose metronomic cyclophosphamide in hormone refractory prostate cancer (HRPC) patients

被引：0
|
作者：
Cipolla, B. G. [1 ,2 ]
Havouis, R. [1 ]
Moulinoux, J. P. [1 ]
机构：
[1] Univ Rennes 1, CNRS, URA 1529, F-35014 Rennes, France
[2] CHP St Gregoire, Rennes, France
来源：
AMINO ACIDS | 2009年 / 37卷 / 01期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：51 / 52
页数：2
相关论文
共 50 条
  • [31] Metronomic Cyclophosphamide and Dexamethasone is Active in Docetaxel, Castration Refractory, Prostate Cancer
    Peel, D.
    Sundar, S.
    CLINICAL ONCOLOGY, 2009, 21 (10) : 801 - 801
  • [32] Randomized study of docetaxel (D) and dexamethasone (DX) with low or high dose estramustine (E) for patients with advanced hormone-refractory prostate cancer (HRPC).
    Nelius, T.
    Klatte, T.
    Reiher, F.
    Filleur, S.
    Yap, R.
    Allhoff, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 254S - 254S
  • [33] Randomised study of docetaxel (D) and dexamethasone (DX) with low or high dose estramustine (E) for patients with advanced hormone-refractory prostate cancer (HRPC)
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 94 - 94
  • [34] Hormone refractory prostate cancer (HRPC): Present and future approaches of therapy
    Di Lorenzo, G
    De Placido, S
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2006, 19 (01) : 11 - 33
  • [35] Phase II clinical trial of metronomic cyclophosphamide (CTX) plus celecoxib (C) and dexamethasone (DEX) in advanced hormone refractory prostate cancer (HRPC): Preliminary clinical and pharmacodynamic results
    Fontana, A.
    Bocci, G.
    D'Arcangelo, M.
    Galli, L.
    Fontana, E.
    Galli, C.
    Landi, L.
    Fioravanti, A.
    Orlandi, P.
    Barletta, M.
    Marsico, R.
    Barsanti, G.
    Andreuccetti, M.
    Del, Tacca M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 82 - 82
  • [36] Phase II study of single agent gemcitabine in patients with hormone refractory prostate cancer (HRPC).
    Nilsson, S
    Holmberg, M
    Ljung, G
    Pettersson-Skjold, D
    Blom, R
    Ullén, A
    Westberg, R
    Nilsson, I
    Lennernas, B
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 432S - 432S
  • [37] A retrospective analysis on 35 patients with hormone-refractory prostate cancer (HRPC) treated with docetaxel
    Carlini, P.
    Felici, A.
    Ruggeri, E. M.
    Moscetti, L.
    Chilelli, M.
    Ciccarese, M.
    Pino, M. S.
    Cecere, F. L.
    Nuzzo, C.
    Sperduti, I
    Pollera, C. F.
    Cognetti, F.
    ANNALS OF ONCOLOGY, 2006, 17 : XI82 - XI82
  • [38] Gene profiling in transurethral resection samples of patients with hormone-refractory prostate cancer (HRPC).
    Stoss, O.
    Albers, P.
    Werther, M.
    Zielinsky, D.
    Jost, N.
    Rueschoff, J.
    Henkel, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 251S - 251S
  • [39] Low-dose metronomic oral cyclophosphamide plus prednisone for metastatic castration resistant prostate cancer (mCRPC) patients
    Martinez Lago, N.
    Anido, U.
    Vieito, M.
    Varela-Ponte, R.
    Carmona, M.
    Rodriguez, C.
    Cortegoso, A.
    Candamio, S.
    Lopez-Lopez, R.
    Leon, L.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S705 - S706
  • [40] Cytoreductive prostate cryoablation and metronomic cyclophosphamide for metastatic hormone-sensitive prostate cancer
    Li, Yonghong
    Wang, Ning
    Zhao, Diwei
    Wang, Jun
    Jiang, Lijuan
    Wang, Yanjun
    Chen, Dong
    Wu, Zhiming
    Zhou, Fangjian
    Yang, Zhenyu
    FUTURE ONCOLOGY, 2022, 18 (19) : 2373 - 2380
12345